Updates are available Correction dated 2022-08-27

Article History

Received: 9 January 2022

Revised: 23 March 2022

Accepted: 28 March 2022

First Online: 16 April 2022

Change Date: 27 August 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12185-022-03440-7

Declarations

:

: YE reports grants or contracts from PharmaEssentia Japan K.K. and Meiji Seika Pharma Co., Ltd; and honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from PharmaEssentia Japan K.K., Novartis Pharma K.K. and Takeda Pharmaceutical Co., Ltd.; and participation on a data safety monitoring board or advisory board from PharmaEssentia Japan K.K. and Novartis Pharma K.K. KO has no conflicts of interest to declare. AG reports research funding from Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., and Nihon Pharmaceutical Co., Ltd; honoraria from Novartis Pharma K.K., Alexion Pharmaceuticals, Inc., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Nihon Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., and Sanofi K.K.; consulting fees from PharmaEssentia Japan K.K., Chugai Pharmaceutical, and Alexion Pharmaceuticals, Inc.; and participation on a data safety monitoring board or advisory board from PharmaEssentia Japan K.K., Chugai Pharmaceutical, and Alexion Pharmaceuticals, Inc. KT reports research funding and consulting fees from Astellas Pharma Inc., PharmaEssentia Japan K.K., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.; and honoraria from Novartis Pharma K.K., Kyowa Kirin Co., Ltd., MSD K.K. Ltd. and Alexion Pharmaceuticals, Inc. HS reports honoraria from Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Celgene K.K., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Sanofi K.K., AstraZeneca K.K., AbbVie G.K., SymBio Pharmaceuticals Ltd., Eisai Co., Ltd., and Kyowa Kirin Co., Ltd.; and research funding from PharmaEssentia Japan K.K., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., Celgene K.K., Novartis Pharma K.K., Sanofi K.K., AstraZeneca K.K., AbbVie G.K., Eisai Co., Ltd., HUYA Bioscience International, LLC., and Chugai Pharmaceutical Co., Ltd.; and scholarship endowment from Astellas Pharma Inc., Teijin Pharma Ltd., Shionogi & Co., Ltd., Eisai Co., Ltd., Sanofi K.K., Taiho Pharmaceutical Co., Ltd., and Nippon Shinyaku Co., Ltd. TaS reports honoraria from Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., SymBio Pharmaceuticals Ltd., Takeda Pharmaceutical Co., Ltd., Celgene K.K., Bristol-Myers Squibb K.K., Kyowa Kirin Co., Ltd., and Pfizer Japan Inc. KU reports research funding from Astellas Pharma Inc., AbbVie GK, Apellis Pharmaceuticals, Inc., SymBio Pharmaceuticals Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Janssen Pharmaceutical K.K., Otsuka Pharmaceutical Co., Ltd., Amgen-Astellas Biopharma K.K., Takeda Pharmaceutical Co., Ltd., Nippon-Shinyaku Co., Ltd., Bristol Myers Squibb K.K., Amgen K.K., Alexion Pharmaceuticals, Inc., Incyte Biosciences Japan G.K., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Celgene K.K., Sumitomo Dainippon Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Mundipharma K.K., Yakult Honsha Co., Ltd., MSD K.K., Gilead Sciences, Inc., and Nippon Boehringer Ingelheim Co., Ltd.; and honoraria from Novartis Pharma K.K., Bristol Myers Squibb K.K., Sanofi K.K., Pfizer Japan Inc., AbbVie GK, Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Astellas Pharma Inc., Alexion Pharmaceuticals, Inc., Eisai Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Celgene K.K., Daiichi Sankyo Co., Ltd., Nippon-Shinyaku Co., Ltd., PharmaEssentia Japan K.K., Yakult Honsha Co., Ltd., SymBio Pharmaceuticals Ltd., and Chugai Pharmaceutical Co., Ltd. KS is a consultant for Sierra and reports research funding from PharmaEssentia Japan K.K., Chugai Pharmaceutical Co., Ltd., AbbVie GK, Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Taisho Pharmaceutical Co., Ltd.; honoraria from Novartis Pharma K.K. and Takeda Pharmaceutical Co., Ltd.; and is a member of an advisory committee for AbbVie GK. MI reports honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Takeda Pharmaceutical Co., Ltd. and Novartis Pharma K.K. SV is an employee of Enhanced Pharmacodynamics, LLC. OZ is an employee of PharmaEssentia Corporation USA. AQ is an employee of PharmaEssentia Corporation, Taiwan. HK, NM and ToS are employees of PharmaEssentia Japan KK. NK is a consultant for AbbVie G.K., Otsuka Pharmaceutical Co., Ltd., Celgene K.K., Japan Tobacco Inc., and PharmaEssentia Japan K.K.; and reports honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Shire Japan K.K., Novartis Pharma K.K., and Takeda Pharmaceutical Co., Ltd.; and is the Chairperson and Executive Director of PharmaEssentia Japan K.K. KK reports honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis Pharma K.K., Takeda Pharmaceutical Co., Ltd., PharmaEssentia Japan K.K., Sanofi K.K., and AbbVie G.K.